MILabs' new Broadband Photon Tomography selected for Innovation of the Year award

NewsGuard 100/100 Score

MILabs is pleased to announce that its new Broadband Photon Tomography technique has been nominated for the Innovation of the Year 2018 award by the World Molecular Imaging Society (WMIS) board of trustees.

Broadband Photon Tomography as implemented on MILabs’ new VECTor6 platform, dramatically expands the versatility and performance of preclinical imaging systems. For the first time, it is possible to perform nuclear and optical molecular imaging techniques on a single platform, enhanced by diagnostic and molecular X-ray CT.  PET and SPECT images can now be acquired at unprecedented high resolutions, even for PET isotopes that exhibit positron ranges of several mm’s such as 82Rb  and 124I, while Optical Images can be visualized in three-dimensions. Moreover, multiple PET isotopes, as well as co-injected PET/SPECT tracers, can be imaged simultaneously and 3D OPT/CT images obtained with single acquisitions.

By imaging a photon energy range from 1eV to 1 MeV. The unique capabilities of Broadband Photon Tomography are expected to extend the application reach of in-vivo animal imaging far beyond the capabilities of current preclinical PET, SPECT, Optical and CT systems.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems